Core Insights - Akari Therapeutics is focused on developing novel payloads for antibody drug conjugates (ADCs), specifically highlighting its innovative PH1 payload and its dual mechanism of action [1][3] - The company aims to advance differentiated therapies for oncology patients through its next-generation ADC discovery platform [1][3] Company Overview - Akari Therapeutics is an oncology biotechnology company that specializes in next-generation spliceosome payload ADCs [3] - The company utilizes an innovative ADC discovery platform to generate and optimize ADC candidates for various targets [3] Product Innovation - The PH1 payload is a spliceosome modulator designed to disrupt RNA splicing in cancer cells, which has shown potential to induce cancer cell death and activate immune responses [3] - Preclinical studies of AKTX-101, an ADC utilizing the PH1 payload, have demonstrated significant activity and prolonged survival compared to traditional ADCs [3] - AKTX-101 has shown potential synergy with checkpoint inhibitors, exhibiting prolonged survival both as a single agent and in combination with these inhibitors [3]